🇺🇸 FDA
Patent

US 10689392

Anti-cancer compounds targeting ral GTPases and methods of using the same

granted A61KA61K31/351A61K31/4162

Quick answer

US patent 10689392 (Anti-cancer compounds targeting ral GTPases and methods of using the same) held by The Regents of the University of Colorado, a Body Corporate expires Mon Jun 18 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of Colorado, a Body Corporate
Grant date
Tue Jun 23 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 18 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
9
CPC classes
A61K, A61K31/351, A61K31/4162, A61K31/437, A61K31/505